Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02723526
Recruitment Status : Unknown
Verified March 2016 by Bo Dai, Fudan University. Recruitment status was: Recruiting
As prostate cancer progresses, tumor cells dissociate and enter the bloodstream. Considered a "liquid biopsy," these circulating tumor cells (CTC) can show how a patient's cancer evolves and responds to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of tumor markers in circulating tumor cells in newly diagnosed metastatic hormone-sensitive prostate cancer patients can predict the outcome of these patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
18 yrs and older, and 80 yrs and younger;
Histologically or cytologically proven prostate adenocarcinoma;
Imaging examinations including Emission Computed Tomography (ECT),Positron Emission Tomography (PET),Computed Tomography(CT)and Magnetic Resonance Imaging (MRI) revealed non-regional lymph node metastasis, bone metastasis, or visceral metastasis;
Not yet receiving hormonal therapy;
Not yet receiving chemotherapy previously;
Not yet receiving radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously;
Patients are willing to participate and can be followed up regularly；
Received radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously;
Received androgen deprivation therapy (including surgical castration, medical castration, anti-androgen therapy, and maximum androgen blockade) before inclusion;
Patients received chemotherapy previously;
Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years);